Simvastatin induces NFκB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells
- 1 December 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 92 (4), 530-543
- https://doi.org/10.1016/j.bcp.2014.09.026
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology, Taiwan
This publication has 70 references indexed in Scilit:
- Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPasesCell Death & Disease, 2013
- Statins, inflammation and deep vein thrombosis: a systematic reviewJournal of Thrombosis and Thrombolysis, 2012
- TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathwayGenes & Development, 2011
- Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteinsTrends in Biochemical Sciences, 2011
- AP-1 (Fra-1/c-Jun)-mediated Induction of Expression of Matrix Metalloproteinase-2 Is Required for 15(S)-Hydroxyeicosatetraenoic Acid-induced AngiogenesisPublished by Elsevier ,2010
- Cytokines and signaling pathways regulating matrix metalloproteinase‐9 (MMP‐9) expression in corneal epithelial cellsJournal of Cellular Physiology, 2009
- E2F – at the crossroads of life and deathTrends in Cell Biology, 2008
- The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsBMC Cancer, 2008
- Statins and cancer preventionNature Reviews Cancer, 2005
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002